SERNYSEPharmaceutical PreparationsFiscal year ends December 31
Serina Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.65−0.07 (-4.07%)
Close on Oct 19, 2026
- Market cap
- $27.04M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
5.5%
1M of 25M shares
Institutional holders
27
5 new, 3 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
7 buys · 27 sales
Net sold $368.71K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Randall Moreadith | 614,961 | 6.80% | 13D (active) | Mar 26, 2024 |
| Juvenescence Limited | 4,400,781 | 27.30% | 13D (active) amendment | Mar 20, 2026 |
| Sio Capital Management, LLC | 1,000,000 | 6.71% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SER | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Sio Capital Management, LLC | 1,000,000 | 3.94% | $1.94M | – | 0.32% |
| Vanguard Capital Management LLC | 162,198 | 0.64% | $314.66K | +3,062 | 0.00% |
| Waverly Advisors, LLC | 67,492 | 0.27% | $130.93K | – | 0.00% |
| Geode Capital Management, LLC | 51,007 | 0.20% | $98.96K | −13,966 | 0.00% |
| Keel Point, LLC | 21,508 | 0.08% | $41.73K | – | 0.00% |
| Northern Trust Corp | 20,771 | 0.08% | $40.30K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 20,009 | 0.08% | $38.82K | – | 0.00% |
| Avidian Wealth Solutions, LLC | 18,800 | 0.07% | $36.47K | – | 0.00% |
| Jane Street Group, LLC | 15,444 | 0.06% | $29.96K | −24,209 | 0.00% |
| State Street Corp | 12,758 | 0.05% | $24.75K | – | 0.00% |
| Caitong International Asset Management Co., Ltd | 3,744 | 0.01% | $7.26K | −238 | 0.00% |
| Wells Fargo & Company/Mn | 3,611 | 0.01% | $7.01K | +5 | 0.00% |
| Tower Research Capital LLC (TRC) | 2,570 | 0.01% | $4.99K | +1,727 | 0.00% |
| BlackRock, Inc. | 2,378 | 0.01% | $4.61K | −55,886 | 0.00% |
| Osaic Holdings, Inc. | 2,002 | 0.01% | $3.88K | +1,001 | 0.00% |
| UBS Group AG | 1,347 | 0.01% | $2.61K | +1,342 | 0.00% |
| Barclays PLC | 545 | 0.00% | $1.06K | New | 0.00% |
| Avion Wealth | 312 | 0.00% | $0 | New | 0.00% |
| Piscataqua Savings Bank | 28 | 0.00% | $54 | – | 0.00% |
| Morgan Stanley | 14 | 0.00% | $28 | +6 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 27 | 1M | 5.5% | 5 / 6 | 4 / 3 | 0M | 0M |
| Q1 2026 | 25 | 1M | 5.8% | 10 / 6 | 1 / 5 | 1M | 0M |
| Q4 2025 | 22 | 0M | 1.7% | 0 / 4 | 6 / 3 | 0M | 0M |
| Q3 2025 | 25 | 0M | 1.8% | 6 / 7 | 2 / 4 | 0M | 0M |
| Q2 2025 | 23 | 0M | 1.6% | 3 / 4 | 5 / 5 | 0M | 0M |
| Q1 2025 | 25 | 0M | 1.3% | 3 / 5 | 6 / 3 | 0M | 0M |
| Q4 2024 | 25 | 0M | 1.3% | 2 / 4 | 5 / 2 | 0M | 0M |
| Q3 2024 | 25 | 0M | 1.2% | 6 / 5 | 6 / 0 | 0M | 0M |
| Q2 2024 | 20 | 0M | 0.8% | 8 / 6 | 2 / 1 | 0M | 0M |
| Q1 2024 | 13 | 0M | 0.4% | 13 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SER | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 125,805 | 0.50% | $244.06K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 45,248 | 0.18% | $83.26K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 33,331 | 0.13% | $64.66K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 4,739 | 0.02% | $8.72K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 2,592 | 0.01% | $4.77K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 2,495 | 0.01% | $4.84K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Steven A. Ledger | Chief Executive Officer, Director | 238,027 | 0.94% | May 27, 2026 |
| Srini Tenjarla | SVP, CMC & Formulation | – | – | May 26, 2026 |
| Randall Moreadith | Chief Scientific Officer | 6,500 | 0.03% | May 26, 2026 |
| Gregory S. Curhan | Chief Financial Officer | – | – | May 26, 2026 |
| Farrell Simon | Director | – | – | Jul 23, 2026 |
| Stephen K. Brannan | Director | 1,000 | 0.00% | Jul 9, 2026 |
| Karen J. Wilson | Director | 30,100 | 0.12% | Jun 22, 2026 |
| Richard Peter Marshall | Director | 12,183 | 0.05% | Jun 22, 2026 |
| Jay Venkatesan | Director | 232,294 | 0.91% | Jun 22, 2026 |
| Gregory Bailey | Director | 1,897,445 | 7.47% | Jun 22, 2026 |
| Simba Gill | Director | – | – | Feb 17, 2026 |
| Ltd Juvenescence | 10% owner | 6,034,376 | 23.76% | Feb 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Stephen K. Brannan Director | Jul 7, 2026 | Buy | +1,000 | $2.03 | $2.03K | 1,000 |
| Jay Venkatesan Director | Jun 17, 2026 | Conversion | +224,152 | $2.25 | $504.34K | 231,705 |
| Gregory Bailey Director | Jun 17, 2026 | Conversion | +1,770,805 | $2.25 | $3.98M | 1,897,445 |
| Gregory Bailey Director | Jun 17, 2026 | Conversion | +6,666,667 | $2.25 | $15.00M | 8,564,382 |
| Karen J. Wilson Director | Jun 12, 2026 | Buy | +5,000 | $1.77 | $8.85K | 10,100 |
| Karen J. Wilson Director | Jun 11, 2026 | Buy | +5,100 | $1.75 | $8.93K | 5,100 |
| Steven A. Ledger Chief Executive Officer, Director | May 26, 2026 | Award | +10,100 | $1.93 | $19.49K | 10,100 |
| Jay Venkatesan Director | May 22, 2026 | Buy | +589 | $1.78 | $1.05K | 589 |
| Karen J. Wilson Director | May 22, 2026 | Buy | +10,000 | $1.93 | $19.30K | 20,000 |
| Karen J. Wilson Director | May 21, 2026 | Buy | +10,000 | $1.77 | $17.70K | 10,000 |
| Richard Peter Marshall Director | May 19, 2026 | Buy | +12,183 | $1.65 | $20.10K | 12,183 |
| Gregory Bailey Director | Mar 31, 2026 | Award | +59,667 | $1.94 | $115.75K | 126,910 |
| Jay Venkatesan Director | Mar 31, 2026 | Award | +7,553 | $1.94 | $14.65K | 7,553 |
| Randall Moreadith Chief Scientific Officer | Mar 23, 2026 | Option exercise | +6,500 | $0.06 | $390 | 6,500 |
| Randall Moreadith Chief Scientific Officer | Mar 23, 2026 | Sale(10b5-1 plan) | −6,500 | $2.86 | $18.59K | 0 |
| Randall Moreadith Chief Scientific Officer | Mar 19, 2026 | Sale(10b5-1 plan) | −39,000 | $2.50 | $97.50K | 0 |
| Randall Moreadith Chief Scientific Officer | Mar 19, 2026 | Option exercise | +39,000 | $0.06 | $2.34K | 39,000 |
| Randall Moreadith Chief Scientific Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −6,500 | $3.03 | $19.70K | 0 |
| Randall Moreadith Chief Scientific Officer | Feb 2, 2026 | Option exercise | +6,500 | $0.06 | $390 | 6,500 |
| Randall Moreadith Chief Scientific Officer | Jan 28, 2026 | Sale(10b5-1 plan) | −6,500 | $3.57 | $23.21K | 0 |
| Randall Moreadith Chief Scientific Officer | Jan 28, 2026 | Option exercise | +6,500 | $0.06 | $390 | 6,500 |
| Randall Moreadith Chief Scientific Officer | Jan 22, 2026 | Sale(10b5-1 plan) | −2,500 | $2.95 | $7.38K | 0 |
| Randall Moreadith Chief Scientific Officer | Jan 22, 2026 | Option exercise | +2,500 | $0.06 | $150 | 2,500 |
| Randall Moreadith Chief Scientific Officer | Jan 21, 2026 | Option exercise | +2,000 | $0.06 | $120 | 2,000 |
| Randall Moreadith Chief Scientific Officer | Jan 21, 2026 | Sale(10b5-1 plan) | −2,000 | $3.00 | $6.00K | 0 |
| Randall Moreadith Chief Scientific Officer | Jan 20, 2026 | Sale(10b5-1 plan) | −2,000 | $3.07 | $6.14K | 0 |
| Randall Moreadith Chief Scientific Officer | Jan 20, 2026 | Option exercise | +2,000 | $0.06 | $120 | 2,000 |
| Randall Moreadith Chief Scientific Officer | Jan 14, 2026 | Sale(10b5-1 plan) | −1,084 | $2.50 | $2.71K | 0 |
| Randall Moreadith Chief Scientific Officer | Jan 14, 2026 | Option exercise | +1,084 | $0.06 | $65 | 1,084 |
| Randall Moreadith Chief Scientific Officer | Jan 13, 2026 | Option exercise | +5,416 | $0.06 | $325 | 5,416 |
| Randall Moreadith Chief Scientific Officer | Jan 13, 2026 | Sale(10b5-1 plan) | −5,416 | $2.50 | $13.54K | 0 |
| Randall Moreadith Chief Scientific Officer | Jan 8, 2026 | Option exercise | +13,000 | $0.06 | $780 | 13,000 |
| Randall Moreadith Chief Scientific Officer | Jan 8, 2026 | Sale(10b5-1 plan) | −13,000 | $2.69 | $34.97K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 23, 2025 | Option exercise | +4,100 | $0.06 | $246 | 4,100 |
| Randall Moreadith Chief Scientific Officer | Dec 23, 2025 | Sale(10b5-1 plan) | −4,100 | $2.60 | $10.66K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 22, 2025 | Option exercise | +5,673 | $0.06 | $340 | 5,673 |
| Randall Moreadith Chief Scientific Officer | Dec 22, 2025 | Sale(10b5-1 plan) | −5,673 | $2.67 | $15.15K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 16, 2025 | Option exercise | +3,227 | $0.06 | $194 | 3,227 |
| Randall Moreadith Chief Scientific Officer | Dec 16, 2025 | Sale(10b5-1 plan) | −3,227 | $2.96 | $9.55K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 12, 2025 | Option exercise | +1,700 | $0.06 | $102 | 1,700 |
| Randall Moreadith Chief Scientific Officer | Dec 12, 2025 | Sale(10b5-1 plan) | −1,700 | $3.26 | $5.54K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 11, 2025 | Option exercise | +3,555 | $0.06 | $213 | 3,555 |
| Randall Moreadith Chief Scientific Officer | Dec 11, 2025 | Sale(10b5-1 plan) | −3,555 | $3.24 | $11.52K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 10, 2025 | Sale(10b5-1 plan) | −645 | $3.35 | $2.16K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 10, 2025 | Award | +645 | $0.06 | $39 | 645 |
| Randall Moreadith Chief Scientific Officer | Dec 9, 2025 | Sale(10b5-1 plan) | −600 | $3.31 | $1.99K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 9, 2025 | Option exercise | +600 | $0.06 | $36 | 600 |
| Randall Moreadith Chief Scientific Officer | Dec 3, 2025 | Option exercise | +5,000 | $0.06 | $300 | 5,000 |
| Randall Moreadith Chief Scientific Officer | Dec 3, 2025 | Sale(10b5-1 plan) | −5,000 | $3.52 | $17.60K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 2, 2025 | Option exercise | +1,500 | $0.06 | $90 | 1,500 |
| Randall Moreadith Chief Scientific Officer | Dec 2, 2025 | Sale(10b5-1 plan) | −1,500 | $3.91 | $5.87K | 0 |
| Randall Moreadith Chief Scientific Officer | Nov 25, 2025 | Sale(10b5-1 plan) | −5,965 | $3.90 | $23.26K | 5,965 |
| Randall Moreadith Chief Scientific Officer | Nov 25, 2025 | Option exercise | +5,965 | $0.06 | $358 | 11,930 |
| Randall Moreadith Chief Scientific Officer | Nov 24, 2025 | Option exercise | +535 | $0.06 | $32 | 535 |
| Randall Moreadith Chief Scientific Officer | Nov 24, 2025 | Sale(10b5-1 plan) | −535 | $3.94 | $2.11K | 0 |
| Randall Moreadith Chief Scientific Officer | Nov 18, 2025 | Option exercise | +6,500 | $0.06 | $390 | 6,500 |
| Randall Moreadith Chief Scientific Officer | Nov 18, 2025 | Sale(10b5-1 plan) | −6,500 | $3.75 | $24.38K | 0 |
| Randall Moreadith Chief Scientific Officer | Nov 10, 2025 | Sale(10b5-1 plan) | −6,500 | $4.10 | $26.65K | 0 |
| Randall Moreadith Chief Scientific Officer | Nov 10, 2025 | Option exercise | +6,500 | $0.06 | $390 | 6,500 |
| Randall Moreadith Chief Scientific Officer | Nov 5, 2025 | Option exercise | +3,398 | $0.06 | $204 | 3,398 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Randall Moreadith Officer | Jan 20, 2026 | 91,000 | $279.37K | Jan 20, 2026 | Option Exercise |
| Randall Moreadith Officer | Oct 14, 2025 | 88,826 | $530.16K | Oct 13, 2025 | Option Exercise |
| Randall Moreadith Officer | Jun 30, 2025 | 99,674 | $576.06K | Jun 30, 2025 | Option Exercise |